Scythian Biosciences Corp (SCYB.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in thousands)
| 09-2024 | 09-2023 | 09-2022 | 09-2021 | 09-2020 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 1,669 | 1,596 | 950 | 849 | 406 |
| Accounts receivable | 1,072 | 1,954 | -296 | -2,325 | -72 |
| Accounts payable and accrued liabilities | 1,758 | 1,980 | 682 | 118 | 1,246 |
| Other Working Capital | 3,876 | -1,438 | 4,328 | -2,681 | 1,176 |
| Other Operating Activity | -14,260 | -18,933 | -10,496 | -6,656 | -5,220 |
| Operating Cash Flow | $-5,885 | $-14,841 | $-4,832 | $-10,696 | $-2,464 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -189 | -348 | -58 | 0 |
| Net Acquisitions | -7 | 0 | 322 | -1,100 | N/A |
| Other Investing Activity | 31 | -3 | 0 | 0 | 0 |
| Investing Cash Flow | $24 | $-193 | $-26 | $-1,158 | $0 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -382 | N/A | N/A | N/A | 858 |
| Debt Issued | 1,856 | N/A | N/A | 63 | 208 |
| Debt Repayment | -271 | 0 | -10 | -81 | -99 |
| Common Stock Issued | 824 | 14,188 | 0 | 6,347 | 2,091 |
| Common Stock Repurchased | N/A | 0 | -331 | -343 | N/A |
| Other Financing Activity | 3,792 | 846 | -120 | 10,658 | 90 |
| Financing Cash Flow | $5,819 | $15,034 | $-460 | $16,645 | $3,148 |
| Beginning Cash Position | 201 | 368 | 5,687 | 896 | 212 |
| End Cash Position | 159 | 369 | 368 | 5,687 | 896 |
| Net Cash Flow | $-42 | $1 | $-5,319 | $4,791 | $684 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,885 | -14,841 | -4,832 | -10,696 | -2,464 |
| Capital Expenditure | N/A | -189 | -348 | -58 | N/A |
| Free Cash Flow | -5,885 | -15,030 | -5,181 | -10,754 | -2,464 |